The diagnostic and prognostic value of osteopontin in patients with pancreatic cancer: A meta-analysis

Abstract

Objective To study the expression of osteopontin (OPN) in pancreatic cancer and to determine its prognostic significance. Methods Studies which evaluated the relationship between the expression of OPN and pancreatic cancer published up to May 2018 were found by searching the electronic databases which included the PubMed, Embase, Cochrane Library, CNKI, Wanfang and VIP. The RevMan 5.3 was used to analyze the data in this meta-analysis by determining the odds ratios (ORs) and their 95% confidence intervals (CIs). Results Using our predetermined selection criteria, this meta-analysis included 13 studies, with 1073 cases of pancreatic cancer tissues in the case group and 346 cases of normal tissues in the control group. The results indicated OPN was over expressed in pancreatic cancers (OR=8.13, 95%CI: 6.00~11.02; P<0.05). The differences in the expressions of OPN between the well differentiation group and the moderate-poor differentiation group (OR=0.37, 95%CI: 0.25~0.57; P<0.05), between the clinical stage Ⅰ-Ⅱ group and the clinical stage Ⅲ-Ⅳ group (OR=0.23, 95%CI: 0.14~0.38; P<0.05), and between the lymph node metastasis group and the no lymph node metastasis group (OR=3.77, 95%CI: 1.99~7.13; P<0.05) were significant. The expressions of OPN did not correlate with gender, age and location of pancreatic cancer. Conclusions Current evidence indicated that OPN was significantly correlated with pancreatic cancer and its clinicopathological features. OPN could be used as an effective diagnostic and survival evaluation marker. Key words: Pancreatic neoplasms; Diagnosis; Osteopontin (OPN); Case-control study; Meta-analysis